💉Acute pancreatitis is no longer just about fluids and pain control. Our understanding of acute pancreatitis has changed dramatically over the past decade. What was once considered a disease driven primarily by pancreatic autodigestion is now recognized as a complex interaction between calcium dysregulation, mitochondrial dysfunction, impaired autophagy, innate immunity, inflammatory signaling, and multiple forms of programmed cell death. These mechanisms ultimately determine whether a patient experiences a mild, self-limited illness or progresses to persistent organ failure. This comprehensive 2026 review highlights how advances in molecular biology are reshaping clinical practice. Early management still relies on aggressive supportive care, but risk stratification is becoming increasingly sophisticated. Traditional scores such as BISAP, APACHE II, SOFA, CTSI, and the revised Atlanta Classification remain essential, yet their greatest limitation is that they often describe disease severity after the inflammatory cascade is already established rather than predicting it early enough to change outcomes. Perhaps the most exciting development is the emergence of artificial intelligence. Machine learning models consistently outperform conventional scoring systems for predicting severe acute pancreatitis, organ failure, ICU admission, and mortality. Rather than relying on a few static variables, these models integrate laboratory trends, imaging, physiological parameters, and clinical evolution to generate dynamic risk estimates that may eventually support real-time bedside decision making. The review also reinforces several important practical messages. Gallstones remain the leading global cause of acute pancreatitis, followed by hypertriglyceridemia and alcohol, although regional differences are substantial. Serum lipase should be preferred over amylase for diagnosis because of its superior sensitivity and specificity, while contrast-enhanced CT remains the cornerstone for assessing complications, ideally after the first 72 hours when necrosis becomes more accurately defined. For intensivists, the future of pancreatitis management will likely move beyond supportive therapy toward precision medicine. Biomarkers, explainable artificial intelligence, transcriptomics, metabolomics, and immunophenotyping may soon identify patients who require individualized interventions before irreversible organ dysfunction develops. Acute pancreatitis remains one of the most challenging inflammatory diseases encountered in critical care. The next major breakthrough will probably not be a new drug, but earlier recognition of the patient who is about to deteriorate. Reference Hu, Q., Hu, Y., Tan, C., Yang, Y., Su, H., Huang, Z., Tang, W., Wang, R., Liu, J., & Wan, M. (2026). Acute pancreatitis: Mechanisms and therapeutic approaches. Signal Transduction and Targeted Therapy, 11, 15. doi.org/10.1038/s41392-025-0…